Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
2(33%)
Results Posted
100%(2 trials)
Terminated
2(33%)

Phase Distribution

Ph not_applicable
3
50%
Ph early_phase_1
1
17%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
N/ANon-phased studies
3(75.0%)

Highest Phase Reached

Early Phase 1

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(2)
Terminated(2)

Detailed Status

Recruiting2
Completed2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
50.0%
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 11 (25.0%)
N/A3 (75.0%)

Trials by Status

recruiting233%
completed233%
terminated233%

Recent Activity

2 active trials
Showing 5 of 6
completedearly_phase_1

Bronchoscopy in Determining the Effect of E-Cigarette Smoking on Biomarkers in the Lungs

NCT03691350
recruiting

Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer

NCT04913311
terminatednot_applicable

Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes

NCT02134717
recruiting

Multidimensional Phenotype Classification in Grade 3 Bronchopulmonary Dysplasia

NCT06475976
completednot_applicable

Combined Diagnostic Approach for Refractory Mycoplasma Pneumonia in Children

NCT07064278
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03691350Early Phase 1

Bronchoscopy in Determining the Effect of E-Cigarette Smoking on Biomarkers in the Lungs

Completed
NCT04913311

Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer

Recruiting
NCT02134717Not Applicable

Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes

Terminated
NCT06475976

Multidimensional Phenotype Classification in Grade 3 Bronchopulmonary Dysplasia

Recruiting
NCT07064278Not Applicable

Combined Diagnostic Approach for Refractory Mycoplasma Pneumonia in Children

Completed
NCT02937402Not Applicable

Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors in Patients With Non-small Cell or Small Cell Lung Cancer

Terminated

All 6 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
6